Novacyt New Combined Assay Approved in UK Under Coronavirus Regulations

By Joe Hoppe

 
Novacyt SA said Wednesday that its Winterplex combined assay test has been approved for use in the U.K. under the country’s coronavirus test approvals’ regulations.
 
The Anglo-French biotechnology group said that the Real-Time PCR SARS-CoV-2 Winterplex 3G assay panel is the sixth of its PCR tests to be added to the U.K.’s CTDA register of approved coronavirus diagnostic products.
      

       
The Winterplex assay can detect influenza A, influenza B, respiratory syncytial virus or RSV, and SARS-CoV-2, or Covid-19. The company said the approval comes in advance of the winter virus season in the northern hemisphere, and will allow healthcare systems to differentiate between common respiratory infections with similar symptoms.
 
“This latest approval ensures we are well-positioned with our consolidated Covid-19 portfolio for any potential future outbreaks and as we continue to focus on our wider respiratory product offering as part of our growth strategy,” Chief Executive David Allmond said.
 
Write to Joe Hoppe at joseph.hoppe@wsj.com